Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a potent inhibitor of DNA methylation, used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Decitabine is a potent inhibitor of DNA methylation, used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 NWCwdJZFTnWwY4Tpc44hSXO|YYm= NEXrR4kxNjYEoN88US=> NYPi[GlPOjRiaB?= M3LJcJdifGW{ NU\RU48ydW:mdXzheIV{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gUWFITS2DIH3lcYJmenN? MUWyOVEzOzB6Mh?=
Eca109 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PqdFAvPS9{LkWvOUDPxE1? NGPCXFYzPC92OD:3NkBp NET0XZp4[XSnch?= M2H0VolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MVmyOVEzOzB6Mh?=
Eca109 MnTESpVv[3Srb36gRZN{[Xl? NHTuSWgxNjYEoN88US=> MU[2M|EzNzJ2IHi= NEmxNWd4[XSnch?= Mo\sbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?= NWLneo9lOjVzMkOwPFI>
Eca109 MmfvSpVv[3Srb36gRZN{[Xl? NGPkcngxNjYEoN88US=> NI\yZVIzPCCq NHjiSlF4[XSnch?= MVjpcohq[mm2czDj[YxtKGmwdnHzbY9v MUWyOVEzOzB6Mh?=
Eca109 NGfQfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknqNE42yqEQvF2= NGj0bZczPCCq Mkf6e4F1\XJ? M3:0XYlv\HWlZYOgS|IwVSCjcoLld5QhcW5idHjlJINmdGxiY4njcIU> NV\EPIhsOjVzMkOwPFI>
Eca109 MoOySpVv[3Srb36gRZN{[Xl? MmT4NE42NzFizszN M2frNFI1KGh? Mmr5e4F1\XJ? MUjk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MUCyOVEzOzB6Mh?=
SW1116  M3zJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLRcFUxNjVxMT:yM|Uh|ryP Ml74OFghcA>? M{[3OmROW09? MUflcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u NFL3bHkzPDh5NEK4Oi=>
LOVO MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TISlAvPS9zL{KvOUDPxE1? NYDKO3JiPDhiaB?= NUPNeoRvTE2VTx?= NInNemlmdmijbnPld{B1cGViR3XmbZRqdmmkIHnu[JVk\WRiY3XscEBqdmirYnn0bY9v MWmyOFg4PDJ6Nh?=
SW1116  NXns[FlQTnWwY4Tpc44hSXO|YYm= NHfiR5gyOCEQvF2= MVu0PEBp MmLISG1UVw>? M4WwSolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MUiyOFg4PDJ6Nh?=
LOVO M3PObGZ2dmO2aX;uJGF{e2G7 NUGzSoRYOTBizszN M4LPPVQ5KGh? M4L4cGROW09? NHywV2lqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? M4fIcFI1QDd2Mki2
SW1116  M4f4cWFxd3C2b4Ppd{BCe3OjeR?= MkniNVAh|ryP NV7rSnJFPDhiaB?= NIDrdlhFVVOR MlLW[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz NH7sPWQzPDh5NEK4Oi=>
LOVO NF[0bpJCeG:ydH;zbZMhSXO|YYm= NFHNXZEyOCEQvF2= NWTF[5JnPDhiaB?= MkTwSG1UVw>? MUTlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NE[4fHozPDh5NEK4Oi=>
RPMI-8226 MUPBdI9xfG:|aYOgRZN{[Xl? Mn[5NU8zKM7:TR?= NVH4SVlvPDhxN{KvPVYhcA>? NWe3N3ZDTE2VTx?= NVnXSJlmcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MX6yOFg{OzFyOB?=
OPM-2  NXjjN3c5SXCxcITvd4l{KEG|c3H5 NXnudXJZOS9{IN88US=> NVHQdIpYPzJxOU[vNVIxKGh? M2LyRWROW09? MXLpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MoDyNlQ5OzNzMEi=
JJN3  MXnBdI9xfG:|aYOgRZN{[Xl? MnfqNE42NzFizszN M2Kz[|I1NzR6IHi= NXfIZ4pMTE2VTx?= MYHpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MUKyOFg{OzFyOB?=
NCI-H929  NVm4SmNjSXCxcITvd4l{KEG|c3H5 NYPOOHRvOS9{IN88US=> NFfwNHE4Oi97Nj:xNlAhcA>? MYXEUXNQ M3u0WYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M4\6[lI1QDN|MUC4
RPMI-8226 M4D6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVSxM|Ih|ryP MUiyOE81QC95MjDo NIXJ[ZdFVVOR MWTh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? MX[yOFg{OzFyOB?=
OPM-2  M2fXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXlNU8zKM7:TR?= MVOyOE81QC95MjDo MWDEUXNQ M{nqc4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 Moi4NlQ5OzNzMEi=
JJN3  M3m5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2wMlUwOSEQvF2= MmDBNlQwPDhxN{KgbC=> M2jHOWROW09? M3f2c4Fn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 Mom0NlQ5OzNzMEi=
NCI-H929  NHWzfIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDzXW01OS9{IN88US=> M4PteFI1NzR6L{eyJIg> M{TP[WROW09? MYXh[oZm[3S|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>? NE\yRWczPDh|M{GwPC=>
HeLa MXfLbY5ie2ViQYPzZZk> NXzwZ2JEU2l;MUCwNQKBmzVyMECg{txOKG[xcjDoSW5VOQ>? NYXzbndLOjR5OECwPVg>
HeLa NXX2OYI2U2mwYYPlJGF{e2G7 NWjiTGd7U2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz M{fzO|I1PzhyMEm4
HeLa M{nwNGtqdmG|ZTDBd5NigQ>? MX\LbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx M3X4eVI1PzhyMEm4
HeLa M2jJbmtqdmG|ZTDBd5NigQ>? M1fuUGtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> NXHmUYtDOjR5OECwPVg>
NB4 NUe4c3k{TnWwY4Tpc44hSXO|YYm= MXyyMlUwPS95LkWvNVAh|ryP NWHnR215OjRiaB?= MkexSG1UVw>? NGDRcHdqdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi MVWyOFQ5PDh5MB?=
CD4+ CD25− T  MULGeY5kfGmxbjDBd5NigQ>? M{XzPFEwPSEQvF2= M{DDepJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? MlLWNlQ1PzZ|NkC=
BV-173 NYmzSmN7SXCxcITvd4l{KEG|c3H5 NVXae|ZuOC5{NT:wMlUwOC55NT:xJO69VQ>? NX;JS2l1PDhxN{KvPVYhcA>? MnflxsBRSlN? NVfkWlZDcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M{XoWFI1PDJ|NkGz
ML-1 NV\PcWg6SXCxcITvd4l{KEG|c3H5 NHy0XJIxNjJ3L{CuOU8xNjd3L{Gg{txO MoPmOFgwPzJxOU[gbC=> NFrrUovDqFCEUx?= MkHFbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M3POXVI1PDJ|NkGz
HL-60 Ml7vRZBweHSxc3nzJGF{e2G7 MW[wMlI2NzBwNT:wMlc2NzFizszN NEixWZY1QC95Mj:5OkBp NYf0WVRCyqCSQmO= NHPzdGNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> MnzwNlQ1OjN4MUO=
KG-1a MV;BdI9xfG:|aYOgRZN{[Xl? NIPZT4YxNjJ3L{CuOU8xNjd3L{Gg{txO M4faZVQ5Nzd{L{m2JIg> M2[4OOKhWEKV MVfpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK= MmrXNlQ1OjN4MUO=
BV-173 MmDVSpVv[3Srb36gRZN{[Xl? NGHmXpAzPTBxNUCwcm0> NFTse3c1QCCq MlPlxsBRSlN? MUTpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MVqyOFQzOzZzMx?=
CEM NWPhZVdwTnWwY4Tpc44hSXO|YYm= M1jselI2OC93MEDuUS=> MoC5OFghcA>? NV7lPVNqyqCSQmO= NHqwT|NqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= M33WblI1PDJ|NkGz
HL-60 NV7Rb24{TnWwY4Tpc44hSXO|YYm= MlHtNlUxNzVyMH7N MWe0PEBp NXzMfm5KyqCSQmO= MXfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MViyOFQzOzZzMx?=
ML-1 MnnpSpVv[3Srb36gRZN{[Xl? NVr0dIRJOjVyL{WwNI5O NG\B[o81QCCq M3jBVuKhWEKV Ml;kbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MnL2NlQ1OjN4MUO=
DLD-1 NUfo[|lUTnWwY4Tpc44hSXO|YYm= NFuwTWIzPTBxNUCwcm0> MknzOFghcA>? M2PwReKhWEKV MV\kc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm MnztNlQ1OjN4MUO=
HCT-116 MoXRSpVv[3Srb36gRZN{[Xl? Mkm3NlUxNzVyMH7N M1HIUFQ5KGh? M2SyNOKhWEKV Mn\C[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? Mn;ONlQ1OjN4MUO=
U937-A/E-9/14/18  MVPBdI9xfG:|aYOgRZN{[Xl? NV7keoxGOC5yMT:wMlEwOS9zMDFOwG0> M3\LXVQ5KGh? NFPsRo9qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ Mk\INlQ{ODB2NU[=
HT29 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnW2O|IhcA>? NYXUV5V2UUN3ME2xOFAxyrFzN{mg{txO MoDwNlQyPzJyNkG=
SW48 M16zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDhO|IhcA>? MonOTWM2OD1zNT6yxtE3NjJizszN MUKyOFE4OjB4MR?=
HCT116 NEDIZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3SUFg4OiCq M1PVc2lEPTB;MT63xtExNjRizszN M2LFUVI1OTd{ME[x
HepG2 M3zJUWZ2dmO2aX;uJGF{e2G7 MkjmNE42NzFizszN MoHaNlQhcA>? NUTSTGl6TE2VTx?= MYD1dE1z\We3bHH0[YQhfGinIILlcIF1cX[nIF;DWG4zKG2UTlGgZY5lKHC{b4TlbY4h\XiycnXzd4lwdg>? MWiyOFE1Pjh5NB?=
LS174T MlX1SpVv[3Srb36gRZN{[Xl? NInrfZgxNjVxMTFOwG0> MkjHNlQhcA>? NUSzc|M3TE2VTx?= NGLCOIdt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NWPPeG5EOjRzNE[4O|Q>
HepG2 M3zE[mFxd3C2b4Ppd{BCe3OjeR?= M1SxdVEwOTBxMUCwJO69VQ>? M1;TS|ch\A>? MojBSG1UVw>? NFTJdpBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXnwXpFWOjRzNE[4O|Q>
LS174T NHTHd3JCeG:ydH;zbZMhSXO|YYm= NXLGdGJEOS9zMD:xNFAh|ryP MXi3JIQ> MUDEUXNQ MWLpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M1HDTFI1OTR4OEe0
QBC-939 NEnRPHFCeG:ydH;zbZMhSXO|YYm= NUfmNlM3OS9zMD:xNFAh|ryP MWm3JIQ> MnfZSG1UVw>? NE\3fJFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVK2W2dJOjRzNE[4O|Q>
U251 NI\Odo5CeG:ydH;zbZMhSXO|YYm= MUixM|ExNzFyMDFOwG0> MnHuO{Bl MYXEUXNQ NF\COXpqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M{XRO|I1OTR4OEe0
HL-60 M2fUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGxJO69VQ>? MmnHOFghcA>? NVWzW2pGcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= MmfaNlQxODB|MkS=
MDA‑MB‑453 NWDwbo9nTnWwY4Tpc44hSXO|YYm= NUHFOWJPOC5{L{Gg{txO M2r2e|czKGh? MYDjZZV{\XNicnWt[ZhxemW|c3nvckBw\iClbHH1[IlvyqBzwrC= M{Oyb|I{QDR2MkK4
HCC1569 MoDSSpVv[3Srb36gRZN{[Xl? MXywMlIwOSEQvF2= MmrrO|IhcA>? NH;EOYRk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MWeyN|g1PDJ{OB?=
BT‑474 NUG0WGtjTnWwY4Tpc44hSXO|YYm= NF;kOocxNjJxMTFOwG0> NHnxcIg4OiCq NV34WW12[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NWnrVXN4OjN6NESyNlg>
AGS MU\BdI9xfG:|aYOgRZN{[Xl? NXXsPGRiPS9zMD:yNE82OCEQvF2= M2XVPFQ5yqCqwrC= MXjEUXNQ NFPOR2dqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MmKyNlM2QDJ5OES=
A549 M2rMZ2Fxd3C2b4Ppd{BCe3OjeR?= NF\VVG02NzFyL{KwM|UxKM7:TR?= Mni1OFjDqGkEoB?= NGPHS21FVVOR MVLpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> M{ftZVI{PTh{N{i0
AGS  MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjrc4RZPS9zMD:yNE82OCEQvF2= M3uxOFQ5yqCqwrC= MonRSG1UVw>? MWTpcoR2[2W|IFeyM20heGijc3WgZZJz\XO2wrC= NHXQOlMzOzV6Mke4OC=>
Kasumi-1 MoHWRZBweHSxc3nzJGF{e2G7 Mn;4NE42KM7:TR?= M3zjeVQ5yqCqwrC= MU\k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NXzpenBiOjN2OUOzOFg>
OCI-AML3 MWjBdI9xfG:|aYOgRZN{[Xl? Ml\qNk42KM7:TR?= Ml;KOFjDqGkEoB?= MV3k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MV:yN|Q6OzN2OB?=
MV4-11 NGr3W4xCeG:ydH;zbZMhSXO|YYm= NULzRmh7Oi53IN88US=> M{nZRVQ5yqCqwrC= Mon0[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O= MV:yN|Q6OzN2OB?=
NK  Ml23R5l1d3SxeHn0fUBCe3OjeR?= MVewMlAzNTJyIN88US=> MnHDOUBl NWXYS3Az\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?= NFj1ZmgzOzN{OEC4PC=>
NK  NHrvc2lCeG:ydH;zbZMhSXO|YYm= NFHUZosxNjB{LUKwJO69VQ>? MVG1JIQ> MW\k[YNz\WG|ZTDOT{Bk\WyuIIDyc4xq\mW{YYTpc44h[W6mII\pZYJqdGm2eTDhd{B1cGViY3;uZ4VvfHKjdHnvckBqdmO{ZXHz[YQ> MWWyN|MzQDB6OB?=
NK  NF\BO41HfW6ldHnvckBCe3OjeR?= MXmwMlAyNTJyIN88US=> MlrlOUBl M37vTYNifXOnczDofZBwdWW2aInsZZRqd25ib3[gUmsh[2WubIOgbY4h[SCmb4Pl5qCUemW|cH;ud4U> NYK1PZZrOjN|MkiwPFg>
MOLT4/DNR Mkf2SpVv[3Srb36gRZN{[Xl? NFTuNnM2KM7:TR?= MXW0JIQ> NIS1[Gxz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>? MofnNlMxPjB3N{C=
Jurkat/DOX NGDacYhHfW6ldHnvckBCe3OjeR?= NXjvXWlqPSEQvF2= M4XMb|Qh\A>? NYrJOZgzemWmdXPld{BCSkOEMTDtVm5CKGW6cILld5Nqd25? MmrjNlMxPjB3N{C=
MOLT4/DNR NGr1cZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqxOUDPxE1? MlToOEBl NXXGbZdCemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> MnnhNlMxPjB3N{C=
Jurkat/DOX MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLWOUDPxE1? M3\3ZlQh\A>? NX;aWYtKemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=> NH;PTmMzOzB4MEW3NC=>
ccRCC  M13HOGFxd3C2b4Ppd{BCe3OjeR?= MmPQNE4xOS1zMN88US=> M1LhZ|czKGh? MULEUXNQ M{[wZohieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? MUiyNlgzPjR4Nx?=
TNBC  NGm3[XVCeG:ydH;zbZMhSXO|YYm= NWnsRYFxOC5yMT2xNO69VQ>? NYrnUG06PzJiaB?= MV7EUXNQ NGrCdG1p[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w MoH1NlI5OjZ2Nke=
A498 M1L5OWFxd3C2b4Ppd{BCe3OjeR?= M4LEblAvODFvMUFOwG0> NEGxR5Y4OiCq Mlm1SG1UVw>? M3\6Z4lv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> M4LKWlIzQDJ4NE[3
KIJ265T MmDBRZBweHSxc3nzJGF{e2G7 NUe1SZdFOC5yMT2xNO69VQ>? M2O2c|czKGh? NHXLRWtFVVOR NYPCT|hOcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>? M1nzOVIzQDJ4NE[3
MDA-231 NF;zN|RCeG:ydH;zbZMhSXO|YYm= MV:wMlAyNTFyzszN M{PnO|czKGh? M{X0OWROW09? NEDUOWRqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv NWnhNFlROjJ6Mk[0Olc>
BT-20 MX\BdI9xfG:|aYOgRZN{[Xl? MnGzNE4xOS1zMN88US=> NHLFfHA4OiCq NE\heG9FVVOR NIj3cVJqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv MYWyNlgzPjR4Nx?=
U937 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkCzOU0zOCEQvF2= M3T2blI1NzR6L{eyJIg> MYHpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NHHZ[FkzOjd4N{CyNS=>
HL60 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[1MVIxKM7:TR?= M2rNTFI1NzR6L{eyJIg> MkXrbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> M1jmZlIzPzZ5MEKx
U937 MoeyRZBweHSxc3nzJGF{e2G7 NV;mVHFzOTVizszN MViyOE81QC95MjDo MkfhbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUiyNlc3PzB{MR?=
HL60 MUnBdI9xfG:|aYOgRZN{[Xl? NF23N2gyPSEQvF2= M{XiRlI1NzR6L{eyJIg> MkHMbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVzKNZNuOjJ5NkewNlE>
LS411N  NUnyb3lLSXCxcITvd4l{KEG|c3H5 NUO0dFBVOC53IN88US=> MljiO|IhcA>? NGftO|FqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= M4HxNFIzPDZzNkm1
MDA-MB-231 NVvIZ49PSXCxcITvd4l{KEG|c3H5 Mof4NVAh|ryP NEnTdW01QCCq MX\y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4r2S|IyQDh5Nkm3
MCF-7  MWXBdI9xfG:|aYOgRZN{[Xl? M2\tVlExKM7:TR?= M2HSR|Q5KGh? MYPy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2rQe|IyQDh5Nkm3
A375 NFvHRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHBcWMxNjVizszN NGjqb4wyNzVxODDk NYr6bnFjcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= NFTVeGozOTd7Nk[yNi=>
SKMEL1 M12zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX3PGR6OC53IN88US=> NYm1c3I2OS93L{ig[C=> MlzhbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M3;QeFIyPzl4NkKy
SKMEL3 NVXZfmhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlT5NE42KM7:TR?= M17SRVEwPS96IHS= MmXmbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MV6yNVc6PjZ{Mh?=
SKMEL28 NYPNWXV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnScnZVOC53IN88US=> MlGzNU82NzhiZB?= NWfLO4l[cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M4Sy[lIyPzl4NkKy
MeWo NI\PO5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMWm8xNjVizszN NF;SN3EyNzVxODDk MV3pcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NVPBW2ZpOjF5OU[2NlI>
B16 NIfnN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzH[nkxNjVizszN MkfhNU82NzhiZB?= MoP2bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? M{jlNVIyPzl4NkKy
Ly 1 MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6yOEBp MnjrTWM2OD15LkOg{txO MWmyNVc4OjB2OR?=
Ly 7 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fxWlI1KGh? NUHNToFtUUN3ME2xNE44KM7:TR?= NIHVXowzOTd5MkC0PS=>
Su-DHL6 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvMZmozPCCq MWTJR|Ux97zgMkCg{txO MlHxNlE4PzJyNEm=
Ly 10 NEHn[|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWyOEBp NFLiVHRKSzVy78{eNlAh|ryP NVzVZ5pqOjF5N{KwOFk>
RIVA MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6yOEBp M1jTVGlEPTExvK6yNEDPxE1? NVTCUHVtOjF5N{KwOFk>
Su-DHL2 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:1WYdqOjRiaB?= M32zWmlEPTExvK6yNEDPxE1? NHXp[HozOTd5MkC0PS=>
Ly 1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\te|Q5KGh? NVjSbowzUUN3ME2wMlM1KM7:TR?= MXeyNVc4OjB2OR?=
Ly 7 NWPMfVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHezPZU1QCCq MX\JR|UxRTBwMEK1JO69VQ>? NILh[GMzOTd5MkC0PS=>
Su-DHL6 M13Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVu0PEBp NVPiVnhFUUN3MP-8olIxKM7:TR?= M{TKOlIyPzd{MES5
Ly 10 M4P6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEm5[401QCCq M3j5dWlEPTB;MT64JO69VQ>? NIftTIczOTd5MkC0PS=>
RIVA M17YRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTYXXpsPDhiaB?= NXPCcW1yUUN3MP-8olIxKM7:TR?= NVPYU4ZEOjF5N{KwOFk>
Su-DHL2 NXLWO3J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPCeI1zPDhiaB?= NI\ZeoRKSzVyPUG3MlQh|ryP MnX3NlE4PzJyNEm=
Ly 1 NXXSOXBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVi3NkBp NICyc4JKSzVyPUCuNFEh|ryP MX6yNVc4OjB2OR?=
Ly 7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rLTVczKGh? M1TDTmlEPTB;MD6wNVgh|ryP Mn3UNlE4PzJyNEm=
Su-DHL6 M2TPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr1d3lJPzJiaB?= NVjvbItEUUN3ME2xMlYh|ryP NFftN5IzOTd5MkC0PS=>
Ly 10 NX60R2xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvQS5M4OiCq NXfVbWRZUUN3ME2xMlIh|ryP MXWyNVc4OjB2OR?=
RIVA MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWL2RoVkPzJiaB?= NFe5SYJKSzVy78{eNlAh|ryP M1\XRlIyPzd{MES5
Su-DHL2 NXjMblJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TQV|czKGh? NXHSe2psUUN3ME2xNU4zKM7:TR?= MWGyNVc4OjB2OR?=

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795923 Not yet recruiting Lung Cancer|Non-small Cell Lung Cancer Yogen Saunthararajah|Case Comprehensive Cancer Center September 2016 Phase 2
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center September 2016 Phase 0
NCT02846935 Not yet recruiting T-cell Lymphoma|Aggressive B-cell Lymphoma|Non-Hodgkins Lymphomas|Indolent B-cell Lymphoma Yogen Saunthararajah|Case Comprehensive Cancer Center September 2016 Phase 0
NCT02664181 Not yet recruiting Advanced Non-Small Cell Lung Cancer Yogan Saunthararajah|Case Comprehensive Cancer Center July 2016 Phase 2
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 2016 Phase 1
NCT02632721 Recruiting Leukemia, Myeloid, Acute Boehringer Ingelheim June 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID